Physician profile
Erin E Chaney
NPI 1821263914
$21,932.21
in general payments reported to CMS, 2019-2025
59 companies · $1,860 in 2025
The $1,860 reported for 2025 was more than what 77% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,303 · 2020: $2,058 · 2021: $4,510 · 2022: $5,265 · 2023: $3,951 · 2024: $2,985 · 2025: $1,860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,329 · Travel and Lodging: $1,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,328.86 |
| Travel and Lodging | $1,467.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,831.91 | 2021-2025 | Vanta Adaptivestim, Intellis Adaptivestim, Inceptiv |
| Boston Scientific Corporation | $4,250.05 | 2019-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System |
| Vertos Medical, INC. | $2,433.13 | 2020-2022 | |
| Abbvie INC. | $1,296.81 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Si-Bone, INC. | $1,179.81 | 2022-2025 | |
| Medtronic USA, INC. | $711.64 | 2019-2020 | |
| Abbott Laboratories | $686.57 | 2019-2025 | Eterna, Proclaim |
| Forte Bio-Pharma LLC | $526.64 | 2019-2025 | Prolate, Nalocet, Tanlor |
| Stimwave Technologies Incorporated | $490.19 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $389.21 | 2019-2025 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $371.96 | 2019-2023 | Ztlido |
| Allergan, INC. | $363.69 | 2019-2022 | |
| Virtus Pharmaceuticals LLC | $324.64 | 2023-2025 | Levorphanol Tartrate |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $315.87 | 2019-2025 | Relistor |
| Novartis Pharmaceuticals Corporation | $247.99 | 2019-2021 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Chaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.